The Role of Antidepressants in the Management of Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis
CNS Drugs,  Evidence Based Medicine  Clinical Article

Hauser W et al. – The tricyclic antidepressant (TCA) amitriptyline and the serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) duloxetine and milnacipran are first–line options for the treatment of fibromyalgia syndrome (FMS) patients. Physicians and patients should be realistic about the potential benefits of antidepressants in FMS. A small number of patients experience a substantial symptom relief with no or minor adverse effects. However, a remarkable number of patients dropout of therapy because of intolerable adverse effects or experience only a small relief of symptoms, which does not outweigh the adverse effects.

Methods
  • Studies with a randomized controlled trial (RCT) design comparing any types of antidepressants with pharmacological placebo or head–to–head comparisons of different types of antidepressants in FMS patients were included.
  • RCTs in which antidepressants were combined with any other defined treatment or antidepressants were tested against anything but drug placebo were excluded.
  • Patients diagnosed with FMS according to predefined criteria of any age were included.
  • To be included, studies had to assess at least one key domain of FMS (pain, sleep, fatigue, health–related quality of life [HRQOL]) as outcomes of efficacy and report total treatment discontinuation rates and/or dropout rates due to adverse events as outcomes for harms.
  • Data were extracted according to protocols of previous systematic reviews on antidepressants in FMS.
  • Methodology quality was assessed by the van Tulder score.
  • Standardized mean differences (SMD) were calculated for continuous outcomes by means and standard deviations and relative risks (RR) for 30% pain reduction and total dropout rate for comparisons of antidepressants with placebo.
  • Examination of the combined results was performed by a random effects model.
  • The authors used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD.
  • Heterogeneity was tested by the I2 statistic.
  • Thirty–five studies were included in the meta–analysis.

Results
  • The SMDs of serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) on pain, sleep, fatigue, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect size on pain was small and the ones on sleep, fatigue, depression and HRQOL were not substantial.
  • 1481/3528 (42.0%) patients with SNRIs and 737/2304 (32.0%) patients with placebo reported a 30% pain reduction (number needed to treat [NNT] 10.0; 95% CI 8.00, 13.4; I2=4%).
  • The RR of dropouts due to adverse events was 1.83 (95% CI 1.53, 2.18; I2=33%).
  • The SMDs of selective serotonin reuptake inhibitors (SSRIs) on pain, sleep, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain, depression and HRQOL were small and the one on sleep not substantial.
  • 72/198 (36.4%) patients with SSRIs and 40/194 (20.6%) patients with placebo reported a 30% pain reduction (NNT 6.3; 95% CI 4.1, 14.1).
  • The RR of dropouts due to adverse events was 1.60 (95% CI 0.84, 3.04; I2=0%).
  • The SMDs of tricyclic antidepressants (TCAs) on pain, sleep, fatigue and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain and sleep were moderate and the ones on fatigue and HRQOL were small.
  • 140/290 (48.3%) patients with TCAs and 70/252 (27.8%) patients with placebo reported a 30% pain reduction (NNT 4.9; 95% CI 3.5, 8.0).
  • The RR of dropouts due to adverse events was 0.84 (95% CI 0.46, 1.52; I2=0%).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study Journal of Affective Disorders, July 17, 2014    Clinical Article

2 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 28, 2014    Review Article    Clinical Article

3 Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder International Clinical Psychopharmacology, July 3, 2014    Clinical Article

4 A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression Journal of Affective Disorders, July 21, 2014    Evidence Based Medicine

5 Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: A meta-analysis of efficacy and acceptability Clinical Therapeutics, July 14, 2014    Evidence Based Medicine    Review Article

6 The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review Current Drug Targets, July 30, 2014    Review Article

7 Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials Australian and New Zealand Journal of Psychiatry, July 11, 2014    Clinical Article

8 Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials Psychosomatic Medicine, March 20, 2014    Evidence Based Medicine    Review Article    Clinical Article

9 Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants The Journal of Pediatrics, July 16, 2014    Clinical Article

10 Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: A nationwide register-based cohort study in Denmark CNS Drugs, June 18, 2014    Clinical Article

11 Do depression treatments reduce suicidal ideation?: The effects of CBT, IPT, pharmacotherapy, and placebo on suicidality Journal of Affective Disorders, July 24, 2014    Clinical Article

12 Efficacy and acceptability of atypical antipsychotics for the treatment of post-traumatic stress disorder: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials Psychiatry Research, July 2, 2014    Evidence Based Medicine

13 Body mass index identified as an independent predictor of psychiatric readmission The Journal of Clinical Psychiatry, July 9, 2014    Clinical Article

14 Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study European Heart Journal, July 23, 2014

15 Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder American Journal of Health-System Pharmacy, July 8, 2014    Review Article

16 Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder Journal of Affective Disorders, July 18, 2014    Evidence Based Medicine    Clinical Article

17 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis FOCUS, June 16, 2014    Evidence Based Medicine

18 Pretreatment brain states identify likely nonresponse to standard treatments for depression Biological Psychiatry, May 23, 2014    Clinical Article

19 Parental social responsiveness and risk of autism spectrum disorder in offspring JAMA Psychiatry, July 7, 2014    Clinical Article

20 Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: A systematic review of cohort studies Journal of Affective Disorders, July 15, 2014    Evidence Based Medicine    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close